Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $79.97 SGD
Change Today 0.00 / 0.00%
Volume 0.0
As of 5:30 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-reg (LONZ) Snapshot

Open
--
Previous Close
$79.97
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
52.9M
EX-Date
04/9/15
P/E TM
--
Dividend
$2.38
Dividend Yield
4.35%
Current Stock Chart for LONZA GROUP AG-REG (LONZ)

Related News

No related news articles were found.

lonza group ag-reg (LONZ) Related Businessweek News

View More BusinessWeek News

lonza group ag-reg (LONZ) Details

Lonza Group Ltd. supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Specialty Ingredients and Pharma&Biotech. The Specialty Ingredients segment offers consumer care products comprising actives for antidandruff shampoos, and natural and organic cosmetic ingredients; vitamin B compounds; and microbial control solutions, including disinfectants and sanitizers that protect from dangerous and unwanted microbes. This segment also provides custom agricultural manufacturing services to enhance crop yields and food quality; industrial Solutions, including preservatives and biocide blends; products and services that enhance the quality of wood; and sanitizers and other treatment chemicals for pools, spas, water parks, as well as in the treatment of surface waters for drinking, agriculture, irrigation, food processing, and industrial applications. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients (APIs) for drug companies; microbial parenteral API, including antibody fragments, vaccines, cytokines, plasmid DNA, fusion proteins, and PEGylated products; and chemical custom services, such as chemically derived active ingredients, peptide syntheses, antibody drug conjugates, cytotoxic, and small organic molecules. It also offers cell culture, transfection, and molecular biology tools for life-science research; media used in the production of therapeutics; endotoxin detection assays; and products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer, and other disease research areas. This segment serves customers in academic and government institutions, and in biotech and pharmaceutical organizations. Lonza Group Ltd. was founded in 1897 and is headquartered in Basel, Switzerland.

9,721 Employees
Last Reported Date: 07/22/15
Founded in 1897

lonza group ag-reg (LONZ) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.1.3M
Compensation as of Fiscal Year 2014.

lonza group ag-reg (LONZ) Key Developments

Lonza Group Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015; Reiterates Earnings Guidance for the Full Year of 2015

Lonza Group Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported sales of CHF 1,904 million compared to CHF 1,800 million a year ago. EBIT was CHF 192 million compared to CHF 215 million a year ago. Profit before income taxes was CHF 137 million compared to CHF 174 million a year ago. Profit for the period, attributable to the equity holder of the parent was CHF 111 million or CHF 2.11 per diluted share compared to CHF 140 million or CHF 2.68 per diluted share a year ago. Net cash provided by operating activities was CHF 358 million compared to CHF 163 million a year ago. Purchase of property, plant & equipment and intangible assets was CHF 96 million compared to CHF 70 million a year ago. EBITDA was CHF 375 million compared to CHF 362 million a year ago. Operational free cash flow was CHF 299 million compared to CHF 124 million a year ago. Net debt as at June 30, 2015 was CHF 1,842 million compared to CHF 2,113 million a year ago. Core EBITDA was CHF 391 million compared to CHF 368 million a year ago. Core result from operating activities was CHF 260 million compared to CHF 241 million a year ago. Core profit for the period was CHF 166 million or CHF 3.16 per diluted share compared to CHF 162 million or CHF 3.10 per diluted share a year ago. Core RONOA was 16.1% compared to 14.5% a year ago. RONOA was 9.6% compared to 10.5% a year ago. The company reiterated its full-year 2015 outlook with sales growth in reported currency compared with last year's sales. CORE EBIT growth of at least 5% in constant exchange rates. CAPEX expected to remain below CHF 300 million.

Lonza Group Ltd. Announces Agreement with TAP Biosystems Group plc

Lonza Group Ltd. has reached an agreement with TAP Biosystems Group plc to distribute the company's Real Architecture For 3D Tissue, or RAFT, 3D cell culture system. The RAFT System uses a patented absorber technology to create cell layers in high-density collagen that mimic the in vivo environment. This system enables researchers to generate more biologically meaningful data from their cell culture studies. The versatile RAFT Kit is available in a number of formats and is appropriate for analysis using a wide variety of imaging, biochemical and histological techniques. In combination with Lonza's human primary cells and media solutions, the RAFT 3D Cell Culture System empowers researchers to create physiologically relevant cell culture models for use across drug discovery and research applications. The RAFT 3D Cell Culture System has been designed with simple, easy-to-follow protocols that allow researchers to set up 3D cell cultures in under an hour. The RAFT Kit includes a collagen type I solution and biocompatible absorbers, which remove the medium from cell-seeded collagen hydrogels and allow researchers to control both cell concentration and matrix density. RAFT 3D Cell Culture System is a flexible system that supports a variety of formats including 24-well, 96-well and insert-well. The key differentiation of the RAFT System from other platforms is its versatility. This system can be utilized with one cell type, or multiple cell types in parallel. Cells can be cultured within the collagen scaffold, or on top, or both. The addition of permeable membrane cell culture inserts provides other extensions to the system, allowing the generation of barrier models including air-lift models. Furthermore, the system is compatible with a variety of cell types and has already been used to successfully generate 3D cultures in a number of research areas, including oncology, toxicology and neuroscience.

Lonza Group Ltd, H1 2015 Earnings Call, Jul 22, 2015

Lonza Group Ltd, H1 2015 Earnings Call, Jul 22, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LONZ:SP $79.97 SGD 0.00

LONZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ashland Inc $104.97 USD +0.32
Clariant AG SFr.17.45 CHF -0.09
Croda International PLC 2,892 GBp +42.00
Owens Corning $44.29 USD +0.26
PerkinElmer Inc $48.68 USD -0.80
View Industry Companies
 

Industry Analysis

LONZ

Industry Average

Valuation LONZ Industry Range
Price/Earnings 31.8x
Price/Sales 1.8x
Price/Book 3.4x
Price/Cash Flow 32.2x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-REG, please visit www.lonza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.